Exact Mass: 439.2813416

NA 28:8;O2

C28H41NO3 (439.3086276)

Leukotriene E4

C23H37NO5S (439.23923120000006)

Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4 activates contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney (PMID: 12607939, 12432945, 6311078). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent and are able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis through receptor-mediated G-protein linked signaling pathways. Leukotriene E4 (LTE4) is a cysteinyl leukotriene. Cysteinyl leukotrienes (CysLTs) are a family of potent inflammatory mediators that appear to contribute to the pathophysiologic features of allergic rhinitis. Nasal blockage induced by CysLTs is mainly due to dilatation of nasal blood vessels, which can be induced by the nitric oxide produced through CysLT1 receptor activation. LTE4, activate contractile and inflammatory processes via specific interaction with putative seven transmembrane-spanning receptors that couple to G proteins and subsequent intracellular signaling pathways. LTE4 is metabolized from leukotriene C4 in a reaction catalyzed by gamma-glutamyl transpeptidase and a particulate dipeptidase from kidney. (PMID: 12607939, 12432945, 6311078)

Militarinone B

C26H33NO5 (439.23586080000007)

A natural product found in Isaria farinosa.

LysoPE(15:0/0:0)

C20H42NO7P (439.26987520000006)

LysoPE(15:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(15:0/0:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

LysoPE(0:0/15:0)

C20H42NO7P (439.26987520000006)

LysoPE(0:0/15:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(0:0/15:0) is a lysophosphatidylethanolamine or a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

11-trans-LTE4

C23H37NO5S (439.23923120000006)

11-trans-LTE4 is also known as 11-trans-Leukotriene e4 or 11t-LTE4. 11-trans-LTE4 is considered to be practically insoluble (in water) and acidic. 11-trans-LTE4 is an eicosanoid lipid molecule

Dodecanoyl-sn-glycero-3-phosphocholine (isomer 1) (LPC(12:0) i1) † ‡

C20H42NO7P (439.26987520000006)

Dodecanoyl-sn-glycero-3-phosphocholine

C20H42NO7P (439.26987520000006)

3-Hydroxylinoleoylcarnitine

C25H45NO5 (439.32975600000003)

3-Hydroxylinoleoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,12Z)-hydroxyoctadeca-9,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxylinoleoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 3-Hydroxylinoleoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(9Z,12Z)-6-Hydroxyoctadeca-9,12-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(9Z,12Z)-6-Hydroxyoctadeca-9,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9Z,12Z)-6-hydroxyoctadeca-9,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9Z,12Z)-6-Hydroxyoctadeca-9,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9Z,12Z)-6-Hydroxyoctadeca-9,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(11E,13Z)-10-Hydroxyoctadeca-11,13-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(11E,13Z)-10-Hydroxyoctadeca-11,13-dienoylcarnitine is an acylcarnitine. More specifically, it is an (11E,13Z)-10-hydroxyoctadeca-11,13-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11E,13Z)-10-Hydroxyoctadeca-11,13-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11E,13Z)-10-Hydroxyoctadeca-11,13-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(12Z,15Z)-10-Hydroxyoctadeca-12,15-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(12Z,15Z)-10-Hydroxyoctadeca-12,15-dienoylcarnitine is an acylcarnitine. More specifically, it is an (12Z,15Z)-10-hydroxyoctadeca-12,15-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (12Z,15Z)-10-Hydroxyoctadeca-12,15-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (12Z,15Z)-10-Hydroxyoctadeca-12,15-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(11E,13E)-9-Hydroxyoctadeca-11,13-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(11E,13E)-9-Hydroxyoctadeca-11,13-dienoylcarnitine is an acylcarnitine. More specifically, it is an (11E,13E)-9-hydroxyoctadeca-11,13-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (11E,13E)-9-Hydroxyoctadeca-11,13-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (11E,13E)-9-Hydroxyoctadeca-11,13-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(8E,12Z)-10-Hydroxyoctadeca-8,12-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(8E,12Z)-10-Hydroxyoctadeca-8,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (8E,12Z)-10-hydroxyoctadeca-8,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8E,12Z)-10-Hydroxyoctadeca-8,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (8E,12Z)-10-Hydroxyoctadeca-8,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoylcarnitine is an acylcarnitine. More specifically, it is an (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine (9S,10E,12Z)-9-hydroxyoctadeca-10,12-dienoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

N-Eicosapentaenoyl Histidine

C26H37N3O3 (439.2834772)

N-eicosapentaenoyl histidine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is an Eicosapentaenoic acid amide of Histidine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Eicosapentaenoyl Histidine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Eicosapentaenoyl Histidine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

N-[2-(3,4-Dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide

C28H41NO3 (439.3086276)

(5S,6R,7E,9E,11Z,14Z)-6-((R)-2-Amino-2-carboxyethylthio)-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C23H37NO5S (439.23923120000006)

Nvp-aew541

C27H29N5O (439.2371984)

Jolkinolide B

C21H35N3O.2[HNO2] (439.27945520000003)

Macrocentridine

C23H37NO7 (439.2569892)

Salicylihalamide A

C26H33NO5 (439.23586080000007)

DTXSID20991547

C23H37NO7 (439.2569892)

(-)-Panclicin D

C25H45NO5 (439.32975600000003)

Parsonsine

C23H37NO7 (439.2569892)

Circinasine A

C23H37NO7 (439.2569892)

CHEMBL420939

C26H37N3O3 (439.2834772)

Lysolpc

C20H42NO7P (439.26987520000006)

(E,E)-Numismine|1,29-Seco-lunarin|1,29-seco-lunarine|Numismin|numismine

C25H33N3O4 (439.2470938000001)

18-demethyl-14-deacetylpubescenine|18-O-demethyl-14-O-deacetylpubescenine

C23H37NO7 (439.2569892)

lannotinidine D

C26H33NO5 (439.23586080000007)

diploclidine

C27H37NO4 (439.27224420000005)

Alkaloid LBY

C25H33N3O4 (439.2470938000001)

C25H45NO5

C25H45NO5 (439.32975600000003)

Delphinifoline

C23H37NO7 (439.2569892)

N-demethylsambutoxin

C27H37NO4 (439.27224420000005)

Dexymalyngamide C

C24H38ClNO4 (439.24892180000006)

Scutebarbatine Z

C26H33NO5 (439.23586080000007)

[8]-Zingerine

C24H33N5O3 (439.2583268000001)

11-[2-amino-3-(4'-O-methyl-alpha-ribopyranosyloxy)phenyl]undecanoic acid

C23H37NO7 (439.2569892)

axistatin 1

C26H41N5O (439.33109360000003)

3-demethyldeoxymethymycin

C24H41NO6 (439.29337260000005)

(?)-agelasidine E

C23H41N3O3S (439.2868476000001)

sanctolide A

C24H41NO6 (439.29337260000005)

C26H41N5O

C26H41N5O (439.33109360000003)

deoxymalyngamide C

C24H38ClNO4 (439.24892180000006)

Malyngamide F

C24H38ClNO4 (439.24892180000006)

GPP78

C27H29N5O (439.2371984)

NVP-AEW541

C27H29N5O (439.2371984)

Arg Lys His

C18H33N9O4 (439.2655378)

Lys Arg His

C18H33N9O4 (439.2655378)

EXE4;14,15-LTE4

C23H37NO5S (439.23923120000006)

Phe Phe Leu

C25H33N3O4 (439.2470938000001)

lysylhistidylarginine

C18H33N9O4 (439.2655378)

histidylarginyllysine

C18H33N9O4 (439.2655378)

Leu Phe Phe

C25H33N3O4 (439.2470938000001)

Phe Leu Phe

C25H33N3O4 (439.2470938000001)

histidyllysylarginine

C18H33N9O4 (439.2655378)

LPC 12:0

C20H42NO7P (439.26987520000006)

Acquisition and generation of the data is financially supported in part by CREST/JST.

1-lauroyl-sn-glycero-3-phosphocholine

C20H42NO7P (439.26987520000006)

A 1-O-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as lauroyl (dodecanoyl)

Arachidonyl dopamine

C28H41NO3 (439.3086276)

Axistatin1/2

C26H41N5O (439.33109360000003)

LPE 15:0-d5

C20H42NO7P (439.26987520000006)

Ala Pro Pro Arg

C19H33N7O5 (439.25430480000006)

Ala Pro Arg Pro

C19H33N7O5 (439.25430480000006)

Ala Arg Pro Pro

C19H33N7O5 (439.25430480000006)

Gly His Lys Val

C19H33N7O5 (439.25430480000006)

Gly His Val Lys

C19H33N7O5 (439.25430480000006)

Gly Lys His Val

C19H33N7O5 (439.25430480000006)

Gly Lys Val His

C19H33N7O5 (439.25430480000006)

Gly Val His Lys

C19H33N7O5 (439.25430480000006)

Gly Val Lys His

C19H33N7O5 (439.25430480000006)

His Gly Lys Val

C19H33N7O5 (439.25430480000006)

His Gly Val Lys

C19H33N7O5 (439.25430480000006)

His Lys Gly Val

C19H33N7O5 (439.25430480000006)

His Lys Val Gly

C19H33N7O5 (439.25430480000006)

His Val Gly Lys

C19H33N7O5 (439.25430480000006)

His Val Lys Gly

C19H33N7O5 (439.25430480000006)

Ile Asn Pro Pro

C20H33N5O6 (439.24307180000005)

Ile Pro Asn Pro

C20H33N5O6 (439.24307180000005)

Ile Pro Pro Asn

C20H33N5O6 (439.24307180000005)

Lys His Arg

C18H33N9O4 (439.2655378)

Arg His Lys

C18H33N9O4 (439.2655378)

Lys Gly His Val

C19H33N7O5 (439.25430480000006)

Lys Gly Val His

C19H33N7O5 (439.25430480000006)

Lys His Gly Val

C19H33N7O5 (439.25430480000006)

Lys His Val Gly

C19H33N7O5 (439.25430480000006)

Lys Pro Pro Val

C21H37N5O5 (439.27945520000003)

Lys Pro Val Pro

C21H37N5O5 (439.27945520000003)

Lys Val Gly His

C19H33N7O5 (439.25430480000006)

Lys Val His Gly

C19H33N7O5 (439.25430480000006)

Lys Val Pro Pro

C21H37N5O5 (439.27945520000003)

Leu Asn Pro Pro

C20H33N5O6 (439.24307180000005)

Leu Pro Asn Pro

C20H33N5O6 (439.24307180000005)

Leu Pro Pro Asn

C20H33N5O6 (439.24307180000005)

His Arg Lys

C18H33N9O4 (439.2655378)

Asn Ile Pro Pro

C20H33N5O6 (439.24307180000005)

Asn Leu Pro Pro

C20H33N5O6 (439.24307180000005)

Asn Pro Ile Pro

C20H33N5O6 (439.24307180000005)

Asn Pro Leu Pro

C20H33N5O6 (439.24307180000005)

Asn Pro Pro Ile

C20H33N5O6 (439.24307180000005)

Asn Pro Pro Leu

C20H33N5O6 (439.24307180000005)

Pro Ala Pro Arg

C19H33N7O5 (439.25430480000006)

Pro Ala Arg Pro

C19H33N7O5 (439.25430480000006)

Pro Ile Asn Pro

C20H33N5O6 (439.24307180000005)

Pro Ile Pro Asn

C20H33N5O6 (439.24307180000005)

Pro Lys Pro Val

C21H37N5O5 (439.27945520000003)

Pro Lys Val Pro

C21H37N5O5 (439.27945520000003)

Pro Leu Asn Pro

C20H33N5O6 (439.24307180000005)

Pro Leu Pro Asn

C20H33N5O6 (439.24307180000005)

Pro Asn Ile Pro

C20H33N5O6 (439.24307180000005)

Pro Asn Leu Pro

C20H33N5O6 (439.24307180000005)

Pro Asn Pro Ile

C20H33N5O6 (439.24307180000005)

Pro Asn Pro Leu

C20H33N5O6 (439.24307180000005)

Pro Pro Ala Arg

C19H33N7O5 (439.25430480000006)

Pro Pro Ile Asn

C20H33N5O6 (439.24307180000005)

Pro Pro Lys Val

C21H37N5O5 (439.27945520000003)

Pro Pro Leu Asn

C20H33N5O6 (439.24307180000005)

Pro Pro Asn Ile

C20H33N5O6 (439.24307180000005)

Pro Pro Asn Leu

C20H33N5O6 (439.24307180000005)

Pro Pro Gln Val

C20H33N5O6 (439.24307180000005)

Pro Pro Arg Ala

C19H33N7O5 (439.25430480000006)

Pro Pro Val Lys

C21H37N5O5 (439.27945520000003)

Pro Pro Val Gln

C20H33N5O6 (439.24307180000005)

His Lys Arg

C18H33N9O4 (439.2655378)

Pro Gln Pro Val

C20H33N5O6 (439.24307180000005)

Pro Gln Val Pro

C20H33N5O6 (439.24307180000005)

Pro Arg Ala Pro

C19H33N7O5 (439.25430480000006)

Pro Arg Pro Ala

C19H33N7O5 (439.25430480000006)

Pro Val Lys Pro

C21H37N5O5 (439.27945520000003)

Pro Val Pro Lys

C21H37N5O5 (439.27945520000003)

Pro Val Pro Gln

C20H33N5O6 (439.24307180000005)

Pro Val Gln Pro

C20H33N5O6 (439.24307180000005)

Gln Pro Pro Val

C20H33N5O6 (439.24307180000005)

Gln Pro Val Pro

C20H33N5O6 (439.24307180000005)

Gln Val Pro Pro

C20H33N5O6 (439.24307180000005)

Arg Ala Pro Pro

C19H33N7O5 (439.25430480000006)

Arg Pro Ala Pro

C19H33N7O5 (439.25430480000006)

Arg Pro Pro Ala

C19H33N7O5 (439.25430480000006)

Val Gly His Lys

C19H33N7O5 (439.25430480000006)

Val Gly Lys His

C19H33N7O5 (439.25430480000006)

Val His Gly Lys

C19H33N7O5 (439.25430480000006)

Val His Lys Gly

C19H33N7O5 (439.25430480000006)

Val Lys Gly His

C19H33N7O5 (439.25430480000006)

Val Lys His Gly

C19H33N7O5 (439.25430480000006)

Val Lys Pro Pro

C21H37N5O5 (439.27945520000003)

Val Pro Lys Pro

C21H37N5O5 (439.27945520000003)

Val Pro Pro Lys

C21H37N5O5 (439.27945520000003)

Val Pro Pro Gln

C20H33N5O6 (439.24307180000005)

Val Pro Gln Pro

C20H33N5O6 (439.24307180000005)

Val Gln Pro Pro

C20H33N5O6 (439.24307180000005)

11-trans-LTE4

C23H37NO5S (439.23923120000006)

A leukotriene that is the 11-trans-isomer of leukotriene E4.

Platelet-activating factor

C20H42NO7P (439.26987520000006)

PC(O-6:0/6:0)[U]

C20H42NO7P (439.26987520000006)

PC(6:0/O-6:0)[U]

C20H42NO7P (439.26987520000006)

PC(O-12:0/O-1:0)

C21H46NO6P (439.30625860000004)

PC(O-12:0/O-1:0)[U]

C21H46NO6P (439.30625860000004)

1-Dodecanoyllysolecithin

C20H42NO7P (439.26987520000006)

Lysolauroyllecithin

C20H42NO7P (439.26987520000006)

PC(0:0/12:0)[U]

C20H42NO7P (439.26987520000006)

14,15-Leukotriene E4

C23H37NO5S (439.23923120000006)

14,15-LTE4

C23H37NO5S (439.23923120000006)

PE(O-16:0/0:0)

C21H46NO6P (439.30625860000004)

LPE(15:0)

C20H42NO7P (439.26987520000006)

Arvanil

C28H41NO3 (439.3086276)

N-arachidonoyl vanillylamine

C28H41NO3 (439.3086276)

PE(15:0/0:0)

C20H42NO7P (439.26987520000006)

CAY10618

C27H29N5O (439.2371984)

Leukotriene E

C23H37NO5S (439.23923120000006)

A leukotriene that is (7E,9E,11Z,14Z)-icosa-7,9,11,14-tetraenoic acid substituted by a hydroxy group at position 5 (5S) and an L-cystein-S-yl group at position 6 (6R).

CAR 18:2;O

C25H45NO5 (439.32975600000003)

LPE 15:0

C20H42NO7P (439.26987520000006)

LysoPE O-16:0

C21H46NO6P (439.30625860000004)

LPE O-15:1;O

C20H42NO7P (439.26987520000006)

Proversilin C

C26H33NO5 (439.23586080000007)

Proversilin D

C26H33NO5 (439.23586080000007)

Lovastatin acid ammonium salt

C24H41NO6 (439.29337260000005)

(S)-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-imidazol-2-y

C24H34BN3O4 (439.26422340000005)

bis(2-ethylhexyl) (Z)-but-2-enedioate,N-ethenyl-N-methylacetamide

C25H45NO5 (439.32975600000003)

tetradecyldimethyl(3-trimethoxysilylpropyl)ammonium chloride

C22H50ClNO3Si (439.3248300000001)

tert-butyl N-[1-hydroxy-4-[[4-methoxy-3-(3-methoxypropoxy)phenyl]methyl]-5-methylhexan-2-yl]carbamate

C24H41NO6 (439.29337260000005)

SODIUM STEARYL PHTHALAMATE

C26H42NNaO3 (439.3062222000001)

(2S)-1-{[{2[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}[(3-hydroxytricyclo[3.3.1.1(3,7)]dec-1-yl)amino]]acetyl}pyrrolidine-2-carbonitrile

C24H33N5O3 (439.2583268000001)

Benzenemethanaminium,N-hexadecyl-N,N-dimethyl-, bromide (1:1)

C25H46BrN (439.2813416)

1-(1-([1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YL)-1-((TERT-BUTYLDIMETHYLSILYL)OXY)PROPAN-2-YL)-3-(M-TOLYL)UREA

C23H33N5O2Si (439.2403398)

N,N,N-TRIMETHYLOCTADECAN-1-AMINIUM IODIDE

C21H46IN (439.2674826)

Propanedinitrile,[2-(2-propyl)-6-[2-(2,3,6,7-tetrahydro-2,2,7,7-tetramethyl-1H,5H-benzo[ij]quinolizin-9-yl)ethenyl]-4H-pyran

C29H33N3O (439.26234880000004)

(1R,3S,4S)-3-[6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-1H-BENZIMIDAZOL-2-YL]-2-AZABICYCLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID 1,1-DIMETHYLETHYL ESTER

C24H34BN3O4 (439.26422340000005)

N-(4 5-DIHYDRO-5-OXO-1-PHENYL-1H-PYRAZO&

C27H41N3O2 (439.3198606)

{1-[2-Oxo-2-({4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl}amino)ethyl]cyclopentyl}acetic acid hydrochloride (1:1)

C21H34ClN5O3 (439.2350044000001)

1,5-diphenyl-2-[3-(4-pyridin-2-ylpiperazin-1-yl)propyl]pyrazol-3-one

C27H29N5O (439.2371984)

Temiverine hydrochloride hydrate

C24H38ClNO4 (439.24892180000006)

D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators

(1S)-1-{4-[(9AR)-Octahydro-2H-pyrido[1,2-A]pyrazin-2-YL]phenyl}-2-phenyl-1,2,3,4-tetrahydroisoquinolin-6-OL

C29H33N3O (439.26234880000004)

N-(2-phenylphenyl)-8-(4-pyridin-3-yltriazol-1-yl)octanamide

C27H29N5O (439.2371984)

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] pentadecanoate

C20H42NO7P (439.26987520000006)

N-Eicosapentaenoyl Histidine

C26H37N3O3 (439.2834772)

2-(2,4-Dichlorobenzyloxy)aniline

C23H37NO5S (439.23923120000006)

N-[2-(3,4-Dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide

C28H41NO3 (439.3086276)

(9Z,12Z)-6-Hydroxyoctadeca-9,12-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(11E,13E)-9-Hydroxyoctadeca-11,13-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(8E,12Z)-10-Hydroxyoctadeca-8,12-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(11E,13Z)-10-Hydroxyoctadeca-11,13-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(12Z,15Z)-10-Hydroxyoctadeca-12,15-dienoylcarnitine

C25H45NO5 (439.32975600000003)

(9S,10E,12Z)-9-Hydroxyoctadeca-10,12-dienoylcarnitine

C25H45NO5 (439.32975600000003)

2-azaniumylethyl (2R)-3-(hexadecyloxy)-2-hydroxypropyl phosphate

C21H46NO6P (439.30625860000004)

2-dodecanoyl-sn-glycero-3-phosphocholine

C20H42NO7P (439.26987520000006)

A 2-acyl-sn-glycero-3-phosphocholine in which the acyl group is specified as dodecanoyl.

His-Arg-Lys

C18H33N9O4 (439.2655378)

7-[3-(1-Azetidinylmethyl)cyclobutyl]-5-(4-phenylmethoxyphenyl)-4-pyrrolo[2,3-d]pyrimidinamine

C27H29N5O (439.2371984)

1-decyl-2-acetyl-sn-glycero-3-phosphocholine

C20H42NO7P (439.26987520000006)

A 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine in which the alkyl group is specified as decyl.

N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8S,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8R,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8S,9R)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

Lys-His-Arg

C18H33N9O4 (439.2655378)

Arg-Lys-His

C18H33N9O4 (439.2655378)

Lys-Arg-His

C18H33N9O4 (439.2655378)

(5E,8E,11E,14E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]icosa-5,8,11,14-tetraenamide

C28H41NO3 (439.3086276)

N-[[(8R,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8S,9R)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[[(8R,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl(4-oxanylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl(oxan-4-ylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

N-[(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3R)-3-methoxy-2-methyl-4-[methyl(oxan-4-ylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl(oxan-4-ylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[[(8S,9S)-6-[(2S)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,14,15-tetrazabicyclo[10.3.0]pentadeca-12,14-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(4R,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(4R,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5S,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5R,6S,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5S,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

[(8S,9S,10R)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

[(8R,9R,10S)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

[(8S,9R,10R)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

1-[(1R)-2-[cyclopentyl(oxo)methyl]-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]-1-butanone

C25H33N3O4 (439.2470938000001)

(6S,7S,8R)-7-[4-(1-cyclohexenyl)phenyl]-8-(hydroxymethyl)-4-[2-(4-morpholinyl)-1-oxoethyl]-1,4-diazabicyclo[4.2.0]octan-2-one

C25H33N3O4 (439.2470938000001)

N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[[(8R,9S)-6-[(2R)-1-hydroxypropan-2-yl]-8-methyl-5-oxo-10-oxa-1,6,13,14-tetrazabicyclo[10.2.1]pentadeca-12(15),13-dien-9-yl]methyl]-N-methylcarbamic acid 2-methylpropyl ester

C21H37N5O5 (439.27945520000003)

N-[(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-phenylacetamide

C25H33N3O4 (439.2470938000001)

N-[(4S,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(4S,7R,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(4R,7S,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(4S,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(4R,7S,8R)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(4S,7R,8S)-8-methoxy-4,5,7,10-tetramethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5R,6R,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5R,6R,9S)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5S,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

N-[(5R,6S,9R)-5-methoxy-3,6,8,9-tetramethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]benzamide

C25H33N3O4 (439.2470938000001)

3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl(4-oxanylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2R,3S)-3-methoxy-2-methyl-4-[methyl(4-oxanylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

3-(4-fluorophenyl)-1-[(2S)-1-hydroxypropan-2-yl]-1-[(2S,3S)-3-methoxy-2-methyl-4-[methyl(4-oxanylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

3-(4-fluorophenyl)-1-[(2R)-1-hydroxypropan-2-yl]-1-[(2R,3R)-3-methoxy-2-methyl-4-[methyl(4-oxanylmethyl)amino]butyl]urea

C23H38FN3O4 (439.28462)

[(8R,9R,10R)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

[(8R,9S,10R)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

[(8R,9S,10S)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

[(8S,9R,10S)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

[(8S,9S,10S)-9-[4-[(E)-2-phenylethenyl]phenyl]-6-(pyridin-3-ylmethyl)-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol

C29H33N3O (439.26234880000004)

(2S,3S)-1-(cyclohexanecarbonyl)-2-(hydroxymethyl)-N-propan-2-yl-3-[4-[(E)-prop-1-enyl]phenyl]-1,6-diazaspiro[3.3]heptane-6-carboxamide

C26H37N3O3 (439.2834772)

His-Lys-Arg

C18H33N9O4 (439.2655378)

Arg-His-Lys

C18H33N9O4 (439.2655378)

(1S,9R,10R,11R)-12-(cyclobutanecarbonyl)-10-(hydroxymethyl)-11-(piperidine-1-carbonyl)-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one

C25H33N3O4 (439.2470938000001)

[(2R)-3-dodecoxy-2-methoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate

C21H46NO6P (439.30625860000004)

(1R,9S,10S,11S)-12-(cyclobutanecarbonyl)-10-(hydroxymethyl)-11-(piperidine-1-carbonyl)-5-[(E)-prop-1-enyl]-7,12-diazatricyclo[7.2.1.02,7]dodeca-2,4-dien-6-one

C25H33N3O4 (439.2470938000001)

(2-Acetyloxy-3-decoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C20H42NO7P (439.26987520000006)

(2-Hydroxy-3-tridecoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C21H46NO6P (439.30625860000004)

[1-Acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] dodecanoate

C19H38NO8P (439.2334918)

NAGly 13:1/10:0

C25H45NO5 (439.32975600000003)

NAGly 10:0/13:1

C25H45NO5 (439.32975600000003)

3-O-Hexadecyl-sn-glycero-1-O-phosphoethanolamine

C21H46NO6P (439.30625860000004)

Lnape 7:0/N-7:0

C19H38NO8P (439.2334918)

Lnape 6:0/N-8:0

C19H38NO8P (439.2334918)

Lnape 9:0/N-5:0

C19H38NO8P (439.2334918)

Lnape 5:0/N-9:0

C19H38NO8P (439.2334918)

Lnape 8:0/N-6:0

C19H38NO8P (439.2334918)

Lnape 3:0/N-11:0

C19H38NO8P (439.2334918)

Lnape 10:0/N-4:0

C19H38NO8P (439.2334918)

Lnape 2:0/N-12:0

C19H38NO8P (439.2334918)

Lnape 4:0/N-10:0

C19H38NO8P (439.2334918)

Lnape 12:0/N-2:0

C19H38NO8P (439.2334918)

Lnape 11:0/N-3:0

C19H38NO8P (439.2334918)

(2-Butanoyloxy-3-octoxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C20H42NO7P (439.26987520000006)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-octoxypropan-2-yl] heptanoate

C20H42NO7P (439.26987520000006)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-nonoxypropan-2-yl] hexanoate

C20H42NO7P (439.26987520000006)

(3-Nonoxy-2-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C20H42NO7P (439.26987520000006)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] propanoate

C20H42NO7P (439.26987520000006)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] acetate

C20H42NO7P (439.26987520000006)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] butanoate

C20H42NO7P (439.26987520000006)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] pentanoate

C20H42NO7P (439.26987520000006)

15:0 Lyso PE-d5

C20H42NO7P (439.26987520000006)

[3-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-2-heptanoyloxypropyl] heptanoate

C19H38NO8P (439.2334918)

(2-Hexanoyloxy-3-pentanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C19H38NO8P (439.2334918)

(3-Acetyloxy-2-nonanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C19H38NO8P (439.2334918)

(2-Octanoyloxy-3-propanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C19H38NO8P (439.2334918)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-pentanoyloxypropan-2-yl] nonanoate

C19H38NO8P (439.2334918)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] octanoate

C19H38NO8P (439.2334918)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] undecanoate

C19H38NO8P (439.2334918)

(3-Butanoyloxy-2-heptanoyloxypropyl) 2-(trimethylazaniumyl)ethyl phosphate

C19H38NO8P (439.2334918)

[1-[2-Aminoethoxy(hydroxy)phosphoryl]oxy-3-butanoyloxypropan-2-yl] decanoate

C19H38NO8P (439.2334918)

lysoDGTS 14:3

C24H41NO6 (439.29337260000005)

2-[(2-Acetamido-3-hydroxytridecoxy)-hydroxyphosphoryl]oxyethyl-trimethylazanium

C20H44N2O6P+ (439.2936834)

2-[[2-(Hexanoylamino)-3-hydroxynonoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C20H44N2O6P+ (439.2936834)

2-[[2-(Butanoylamino)-3-hydroxyundecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C20H44N2O6P+ (439.2936834)

2-[Hydroxy-[3-hydroxy-2-(pentanoylamino)decoxy]phosphoryl]oxyethyl-trimethylazanium

C20H44N2O6P+ (439.2936834)

2-[[2-(Heptanoylamino)-3-hydroxyoctoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C20H44N2O6P+ (439.2936834)

2-[Hydroxy-[3-hydroxy-2-(propanoylamino)dodecoxy]phosphoryl]oxyethyl-trimethylazanium

C20H44N2O6P+ (439.2936834)

1-pentadecanoyl-glycero-3-phosphoethanolamine

C20H42NO7P (439.26987520000006)

LysoPE(0:0/15:0)

C20H42NO7P (439.26987520000006)

3-hydroxylinoleoylcarnitine

C25H45NO5 (439.32975600000003)

An O-acylcarnitine having 3-hydroxylinoleoyl as the acyl substituent.

eoxin E4

C23H37NO5S (439.23923120000006)

A leukotriene that is the 14R-(S-cysteinyl),15S-hydroxy derivative of (5Z,8Z,10E,12E)-icosa-7,9,11,14-tetraenoic acid.

1-hexadecyl-sn-glycero-3-phosphoethanolamine

C21H46NO6P (439.30625860000004)

1-(2-methoxy-6Z-tetradecenyl)-sn-glycero-3-phosphoethanolamine

C20H42NO7P (439.26987520000006)

MePC(10:0)

C19H38NO8P (439.2334918)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

NA-2AAA 19:1(9Z)

C25H45NO5 (439.32975600000003)

NA-Cys 22:2(13Z,16Z)

C25H45NO3S (439.311998)

NA-Dopamine 20:4(5Z,8Z,11Z,14Z)

C28H41NO3 (439.3086276)

NA-Glu 20:1(11Z)

C25H45NO5 (439.32975600000003)

NA-His 20:5(5Z,8Z,11Z,14Z,17Z)

C26H37N3O3 (439.2834772)

NA-Met 20:2(11Z,14Z)

C25H45NO3S (439.311998)

NA-Taurine 22:4(7Z,10Z,13Z,16Z)

C24H41NO4S (439.2756146000001)

NA-Tyr 18:4(6Z,9Z,12Z,15Z)

C27H37NO4 (439.27224420000005)

CAR 18:2;OH

C25H45NO5 (439.32975600000003)

CAR DC17:2

C24H41NO6 (439.29337260000005)

MGTS 14:3

C24H41NO6 (439.29337260000005)

LPC 12:0/0:0

C20H42NO7P (439.26987520000006)

LPE 15:0/0:0

C20H42NO7P (439.26987520000006)

PE 10:0/4:0

C19H38NO8P (439.2334918)

PE 12:0/2:0

C19H38NO8P (439.2334918)

PE 14:0

C19H38NO8P (439.2334918)

ST 21:1;O5;Gly

C23H37NO7 (439.2569892)

ST 22:0;O4;Gly

C24H41NO6 (439.29337260000005)

ST 24:6;O3;Gly

C26H33NO5 (439.23586080000007)

ST 25:5;O2;Gly

C27H37NO4 (439.27224420000005)

ST 21:2;O2;Tau

C23H37NO5S (439.23923120000006)

CP-868388 (free base)

C26H33NO5 (439.23586080000007)

CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions[1].

Denifanstat

C27H29N5O (439.2371984)

Denifanstat (TVB-2640) is an orally active and potent Fatty Acid Synthase (FASN) inhibitor with an IC50 of 0.052 μM and an EC50 of 0.072 μM. Denifanstat has the potential for fatty liver disease and cancer research[1][2].

11-{2-amino-3-[(3,4-dihydroxy-5-methoxyoxan-2-yl)oxy]phenyl}undecanoic acid

C23H37NO7 (439.2569892)

(1r,2r,3r,4r,5s,6r,8s,9r,10s,13r,16r,17r)-11-ethyl-16-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,5,6,8,17-pentol

C23H37NO7 (439.2569892)

(6s,9s)-3-[(2s)-butan-2-yl]-13-(hexan-2-yl)-5,8,11-trihydroxy-9-isopropyl-6-methyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one

C23H41N3O5 (439.30460560000006)

(1r,4s,8r,9r,14s,20r)-4-hydroxy-4,9-diisopropyl-8-methyl-2,7,12-trioxa-17-azatricyclo[12.5.1.0¹⁷,²⁰]icosane-3,6,11-trione

C23H37NO7 (439.2569892)

11-ethyl-18-methoxy-13-(methoxymethyl)-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecane-4,6,8,9,16-pentol

C23H37NO7 (439.2569892)

(1s,10s,11r,13s,14s,15s)-14-hydroxy-15-methyl-6-azatetracyclo[8.6.0.0¹,⁶.0²,¹³]hexadec-2-en-11-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate

C26H33NO5 (439.23586080000007)